All News

Rates of treatment discontinuation appear to be higher in patients receiving nivolumab plus ipilimumab for cancer than those receiving nivolumab monotherapy.

Investigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.

The FDA companion diagnostic designation for the FoundationOne CDx and FoundationOne Liquid CDx may improve access to treatment with encorafenib plus binimetinib for those with BRAF V600E-mutated non–small cell lung cancer.

Findings from a meta-analysis highlight the effect of varying censorship criteria for the definition of surrogate end points in localized prostate cancer randomized clinical trials.

Those with resectable non–small cell lung cancer can now receive neoadjuvant treatment with pembrolizumab and chemotherapy followed by adjuvant pembrolizumab after approval by the FDA.

Discrepancies in patients with blood cancer who are eligible for but do not undergo hematopoietic stem cell transplant have been observed not only for Black patients, but Hispanic, Asian, and White patients as well, according to Usama Gergis, MD, MBA.

Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.

Findings from the phase 3 TARGET-TP trial support a biomarker-driven primary thromboprophylaxis strategy in adult patients with lung and gastrointestinal cancers as routine care.

Results from the phase 3 FLAURA2 trial allowed for the combination of osimertinib plus chemotherapy to be submitted for priority review.

Nivolumab is now available as an adjuvant treatment for patients with completely resected stage IIB or IIC melanoma following its approval by the FDA based on data from the phase 3 CheckMate-76k trial.

John O. Mascarenhas, MD, led a panel discussion on myelofibrosis management including the use of JAK inhibitors and transplantation.

Those with breast cancer who have undergone implant-based reconstruction following mastectomy have similar outcomes with hypofractionated vs conventionally fractionated radiotherapy.

A patient with bladder cancer recounts his diagnosis while Rohit Jain, MD, and Anand B. Shah, PharmD, BCOP, review treatment options and the toxicity associated with them.

Nelson J. Chao, MD, MBA, and his colleagues discussed the use of ruxolitinib as treatment for patients with graft-vs-host disease.

Clinicians should not dismiss the concerns of younger patients who suspect they may have breast cancer, especially amid an increase in early-onset disease according to Monique Gary, DO, MSc, FACS.

Brian I. Rini, MD, led a panel where he and his colleagues discussed the results of the CLEAR trial and its implications in renal cell carcinoma.

Adding TPST-1120 to atezolizumab and bevacizumab appears to improve progression-free survival compared with atezolizumab and bevacizumab alone in patients with hepatocellular carcinoma.

Data from the phase 2 SAMCO-PRODIGE 54 trial may support the use of immune checkpoint inhibitors over standard second-line therapy in mismatch repair–deficient and/or microsatellite instability–high metastatic colorectal cancer.

Accommodating supportive therapies such as fertility and hair follicle preservation may help increase trial recruitment among younger patients with breast cancer, according to Monique Gary, DO, MSc, FACS.

Investigators report that bendamustine/rituximab debulking appears to decrease tumor lysis syndrome risk in patients with previously untreated chronic lymphocytic leukemia.

Data from a phase 1 study support the orphan drug designation for SLS009 as a treatment for patients with acute myeloid leukemia.

A young woman presents with painless lumps to the emergency department and is later diagnosed with clear cell carcinoma.

Patients diagnosed with BRAF V600E–mutant, metastatic non–small cell lung cancer are now able to undergo treatment with combination encorafenib and binimetinib.

LSAM-PTX plus standard of care appears efficacious in a small population of patients with locally advanced pancreatic cancer.

The FDA companion diagnostic designation for FoundationOne CDx may improve access to treatment with selpercatinib in select patients with solid tumors harboring a RET gene fusion.

CAR-HEMATOTOX scores may enable risk stratification of patients with mantle cell lymphoma prior to treatment with brexucabtagene autoleucel.

Julie M. Vose, MD, MBA, discussed why the need for multidisciplinary care is so pertinent, and how it must continue even after treatment ends.

Over half of all patients with small cell neuroendocrine prostate cancer treated with BXCL701 and pembrolizumab were alive at 1 year in a phase 2 trial.

Elevated white blood cell counts also appear to correlate with shorter overall survival in patients receiving standard induction chemotherapy plus cytarabine for acute myeloid leukemia.

Investigators plan to share data from the phase 3 KEYNOTE-671 trial assessing perioperative pembrolizumab in resectable non–small cell lung cancer with international regulatory health authorities.